Avation Medical

Overview

Avation Medical is a leading neuromodulation and digital health company based in Columbus, Ohio. Founded by Jill Schiaparelli and Manish Vaishya, Avation Medical focuses on developing innovative wearable peripheral neuromodulation technologies. The company has raised over $22 million in equity financing as of 2024, primarily from its successful Series C round. Avation Medical's flagship product, the Vivally System, provides a non-invasive solution for individuals suffering from urinary incontinence and overactive bladder syndrome.

Recent Developments

February 2024: Avation Medical showcased its Vivally System at the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) conference, attracting significant interest from the urology community. The Vivally System, which eliminates the need for surgery, drugs, or needles, is positioned as a game-changer in the treatment of overactive bladder (OAB).
February 2024: The company raised over $22 million in an oversubscribed Series C financing round led by ShangBay Capital and Asahi Kasei, with participation from Angelini Ventures and the JobsOhio Growth Capital Fund. This funding supports the launch and commercialization of the Vivally System in key markets.
April 2024: Avation Medical appointed Michael Hoffman as Vice President of Market Access and Payer Relations, tasked with optimizing market access strategies and coverage negotiations with payers.
March 2024: In an effort to expand market reach, the Vivally System's efficacy and safety were highlighted in multiple published clinical studies, demonstrating its effectiveness in treating patients without the need for surgery or pharmaceuticals.

Attribute	Information
Founding Date	Not specified
Headquarters	Columbus, Ohio, USA
Founders	Jill Schiaparelli, Manish Vaishya
Revenue	Not disclosed
Profits	Not disclosed
Key Investors	ShangBay Capital, Asahi Kasei, Angelini Ventures, JobsOhio Growth Capital Fund
Industry	Neuromodulation, Digital Health
Number of Employees	Not disclosed

Early History

Avation Medical was founded with the goal of revolutionizing the treatment of urinary urgency and incontinence through advanced neuromodulation technology. Jill Schiaparelli and Manish Vaishya, leveraging their experience in healthcare innovation, embarked on developing the Vivally System. The initial phases focused on rigorous research and development, culminating in the creation of a wearable device that addresses a significant gap in treating overactive bladder conditions non-invasively. The company's pioneering approaches quickly garnered attention, leading to substantial investor interest and clinical collaborations.

Company Profile and Achievements

Avation Medical operates at the forefront of wearable neuromodulation technology, aiming to make patient-driven solutions accessible and routine. Its flagship product, the Vivally System, represents a landmark achievement in non-invasive bladder control therapies. Notable achievements include:

FDA Clearance: The Vivally System received FDA 510(k) clearance, underscoring its safety and efficacy as a medical device.
Clinical Trials: The system was validated through robust clinical trials, showing significant improvement in managing overactive bladder symptoms without traditional interventions.
Innovative Technology: The system employs a closed-loop mechanism, personalizing neuromodulation therapy in real-time, ensuring optimal patient outcomes.
Funding Success: The successful Series C funding round allowed Avation Medical to scale production and facilitate market entry across key regions.

Current Operations and Market Position

Currently, Avation Medical focuses on strengthening its market presence with the Vivally System. Positioned as a leader in wearable neuromodulation, the company’s strategic initiatives include:

Market Expansion: Targeting key domestic and international markets for the Vivally System, focusing primarily on regions with high prevalence of overactive bladder conditions.
Innovation Pipeline: Exploring further applications of its neuromodulation technology across other medical conditions, potentially extending beyond urology.
Partnerships and Collaborations: Building alliances with healthcare providers and technology partners to enhance product reach and impact.

Conclusion

Avation Medical stands as a pioneering force in transforming the landscape of neuromodulation therapies. With substantial investment support and groundbreaking technology, the company is poised to redefine treatment paradigms for chronic bladder conditions. Looking forward, Avation Medical's commitment to innovation and patient-centered care anticipates a trajectory marked by expanded market influence and deepened contributions to medical technology advancements.